TG Therapeutics reported a 64% year-over-year increase in Q2 revenue from its multiple sclerosis drug BRIUMVI, reaching $228 million. This strong sales momentum led the company to raise its 2026 revenue guidance to $950 million. Although net income was affected by investments in manufacturing, the upcoming subcutaneous form of BRIUMVI, expected to show Phase 3 data by late 2026 or early 2027, could expand the market and improve future margins. While the stock's valuation is now reasonable rather than deeply discounted, pipeline assets beyond multiple sclerosis provide additional growth potential amid risks like development delays and competition.
The stock market is down significantly due to company-specific news such as acquisitions, missed earnings, and revised outlooks. Key declines include PN Smart Energy dropping over 51% after an acquisition, Inno Holdings falling nearly 48%, and Sportr...
TG Therapeutics reported mixed Q2 2026 results with total revenue of $240.34 million, beating estimates thanks to strong sales of its drug BRIUMVI, which grew over 64% year-over-year. However, earnings per share (EPS) came in at $0.05, significantly ...
TG Therapeutics reported strong second quarter 2026 results with total global revenue of approximately $240 million, including $228 million in U.S. net product revenue from BRIUMVI. The company raised its full year 2026 revenue guidance to about $950...
